Ramona A. Sequeira, President of Takeda Pharmaceutical Company’s worldwide Portfolio Division, has been appointed to the Board of Directors of Organon, a worldwide healthcare organisation that focuses on women’s health, with effect from July 1, 2025. Ms. Sequeira will be a member of the Talent Committee of the Board. The Organon Board will now have 12 directors in conjunction with Ms. Sequeira’s appointment.
With ten years at Takeda and twenty years at Eli Lilly & Company, Ms. Sequeira provides almost thirty years of experience in the pharmaceutical sector. She is an established business leader with a great track record of successful execution in international markets, including the USA, Europe, and emerging markets, and a resolute dedication to developing strategies around patient needs.
“We are excited to strengthen our Board with the appointment of Ramona Sequeira,” said Carrie Cox, Chairman of Organon’s Board of Directors. “Her deep experience in commercial strategy will be a valuable asset to Organon as we continue to seek growth opportunities for our expansive and diverse portfolio.”
Ramona Sequeira serves as President of Takeda’s Global Portfolio Division and is a member of the company’s Global Executive Team. In this capacity, she oversees Takeda’s regional business units in Europe and Canada, China, and Growth and Emerging Markets, as well as the company’s Vaccines Business Unit and the Global Medical and Commercial Strategy functions. She also co-chairs Takeda’s Pipeline Review Committee. Previously, she led Takeda’s U.S. business.
Before joining Takeda, Ms. Sequeira held several senior leadership positions at Eli Lilly, including General Manager for the UK and Northern Europe and Vice President of Lilly USA.
She made history as the first woman to chair the Board of Directors of the Pharmaceutical Research and Manufacturers of America (PhRMA) and has also served on the Board of the Association of the British Pharmaceutical Industry.
Ms. Sequeira is currently a member of the Board of Directors at Edwards Life Sciences. She holds an honors Bachelor of Science degree in molecular genetics and molecular biology from the University of Toronto and an MBA from McMaster University in Canada.
About Organon
Organon is an independent global healthcare company with a mission to help improve the health of women throughout their lives. Organon’s diverse portfolio offers over 70 medicines and products in women’s health, biosimilars, and a large franchise of established medicines across a range of therapeutic areas. In addition to Organon’s current products, the company invests in innovative solutions and research to drive future growth opportunities in women’s health and biosimilars. Organon is also pursuing opportunities to collaborate with biopharmaceutical partners and innovators who look to commercialize their products by leveraging Organon’s scale and agile presence in fast growing international markets.
Organon has geographic scope with significant reach, world-class commercial capabilities, and approximately 10,000 employees with headquarters located in Jersey City, New Jersey.
